Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It contains only specific transaction details:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $43.38 per ADS.
- Transaction Volume: 2 ADSs.
- Transaction Date: July 8, 2016.
Material Changes
No material changes to the company's financial position or operations are reported. The filing documents a minor increase in holdings (2 ADSs) for Dr. K. Slaoui, a PCA of Dr. M. M. Slaoui (Chairman, Global Vaccines). This increase resulted from the revaluation of the cash element of a notional investment within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a specific insider-related transaction.
Investor Verification Points
- Verify the identity of Dr. K. Slaoui and their relationship to Dr. M. M. Slaoui.
- Confirm the transaction was a notional allocation within the GSK 401(K) plan rather than an open market purchase.
- Note that this filing does not reflect broader company performance; refer to Form 20-F for financial results.